Citations

Mayo Clinic

Showing 10 of 108572 citations.

IC‐01‐05: Neuropathologic Features of AV1451 TAU Pet Autoradiography in Dementia
Curran, Geoffry L., Fang, Ping , Josephs, Keith A. , Parisi, Joseph E., Bruinsma, Tyler J. , Petrucelli, Leonard , Cook, Casey , Petersen, Ronald C. , Lowe, Val J. , Murray, Melissa E. , Kantarci, Kejal , Boeve, Bradley F. , Pandey, Mukesh K. , Knopman, David S. , Jones, David T. , Dickson, Dennis W. , Jack, Clifford R.

Alzheimer's & Dementia | October 17, 2016 | Volume: 12 | Issue: 7S_Part_1 | Pages: No page available

10.1016/j.jalz.2016.06.065 Get It

P3‐079: Alzheimer's Disease Family History Modifies Tomm40 Effects on Vascular Risk Factors and Neurovascular Pathology
Webb, J. L. , Willette, Auriel A. , Lutz, Michael W. , Wennberg, Alexandra

Alzheimer's & Dementia | October 17, 2016 | Volume: 12 | Issue: 7S_Part_17 | Pages: No page available

10.1016/j.jalz.2016.06.1738 Get It

P4‐027: Combing Evidence Across Multiple Cohorts for Systems‐Based Target Discovery: the AMP‐AD Knowledge Portal
Allen, Mariet , Funk, Corey, Xu, Jishu , Logsdon, Ben , Yu, Lei , Schuyler, Sarah, Friend, Stephen , Schadt, Eric , Jager, Philip L. De , Ertekin‐Taner, Nilüfer , Dang, Kristen K. , Perumal, Thanneer Malai , Wang, Minghui , Bennett, David A. , Zhang, Bin , Price, Nathan D. , Mangravite, Lara M.

Alzheimer's & Dementia | October 17, 2016 | Volume: 12 | Issue: 7S_Part_21 | Pages: No page available

10.1016/j.jalz.2016.06.2116 Get It

O2‐03‐02: are White Matter Hyperintensities a Core Feature of Alzheimer’s Disease or Just a Reflection of Amyloid Angiopathy? Evidence From the Dominantly Inherited Alzheimer Network (DIAN)
Zimmerman, Molly E. , Viqar, Fawad, Narkhede, Atul, Benzinger, Tammie Lee Smith, Marcus, Daniel S., Cairns, Nigel J. , Buckles, Virginia, Saykin, Andy J., Ringman, John M. , Ryan, Natalie S. , Förster, Stefan , Laske, Christoph , Salloway, Stephen , Correia, Stephen , Weiner, Michael W. , Mayeux, Richard , Lee, Seonjoo , Tosto, Giuseppe , Goate, Alison , Fox, Nick C. , Holtzman, David M. , Ghetti, Bernardino , McDade, Eric , Martins, Ralph N. , Saykin, Andy J., Masters, Colin L. , Schofield, Peter R. , Sperling, Reisa Anne , Bateman, Randall J. , Morris, John C. , Jack, Clifford R. , Brickman, Adam M.

Alzheimer's & Dementia | October 17, 2016 | Volume: 12 | Issue: 7S_Part_4 | Pages: No page available

10.1016/j.jalz.2016.06.406 Get It

Immunomodulatory Role of Mesenchymal Stem Cell Therapy in Vascularized Composite Allotransplantation
Heyes, Richard , Iarocci, Andrew , Tchoukalova, Yourka D. , Tchoukalova, Yourka , Lott, David G , Lott, David G.

Journal of Transplantation | October 16, 2016 | Volume: 2016 | Issue: No issue available | Pages: 1-10

10.1155/2016/6951693 | PMID 27822384 Get It

This review aims to summarize contemporary evidence of the in vitro and in vivo immunomodulatory effects of mesenchymal stem cells (MSCs) in promoting vascularized composite allotransplant (VCA) tolerance. An extensive literature review was performed to identify pertinent articles of merit. Prospective preclinical trials in mammal subjects receiving VCA (or skin allograft) with administration of MSCs were reviewed. Prospective clinical trials with intravascular delivery of MSCs in human populations undergoing solid organ transplant were also identified and reviewed. Sixteen preclinical studies are included. Eleven studies compared MSC monotherapy to no therapy; of these, ten reported improved graft survival, which was statistically significantly prolonged in eight. Eight studies analyzed allograft survival with MSC therapy as an adjunct to proven immunosuppressive regimens. In these studies, daily immunosuppression was transiently delivered and then stopped. In all studies, treatment-free graft survival was statistically significantly prolonged in animals that received MSC therapy. MSCs have been safely administered clinically and their use in renal transplant clinical trials provides evidence that they improve allograft transplant tolerance in clinical practice. There is potential for MSC induction therapy to overcome many of the obstacles to widespread VCA in clinical practice. Preclinical studies are needed before MSC-induced VCA tolerance becomes a clinical reality.
Prostate Health Index improves multivariable risk prediction of aggressive prostate cancer
Loeb, Stacy , Shin, Sanghyuk S. , Broyles, Dennis L., Wei, John T., Sanda, Martin G. , Klee, George G., Partin, Alan W. , Sokoll, Lori J. , Chan, Daniel W. , Bangma, Chris H. , Schaik, Ron H. N. van , Slawin, Kevin M., Marks, Leonard S. , Catàlona, William J. , Klee, George, Loeb, Stacy

BJU International | October 15, 2016 | Volume: 120 | Issue: 1 | Pages: 61-68

10.1111/bju.13676 | PMID 27743489 Get It

Objective To examine the use of the Prostate Health Index ( PHI ) as a continuous variable in multivariable risk assessment for aggressive prostate cancer in a large multicentre US study. Materials and Methods The study population included 728 men, with prostate‐specific antigen ( PSA ) levels of 2–10 ng/ mL and a negative digital rectal examination, enrolled in a prospective, multi‐site early detection trial. The primary endpoint was aggressive prostate cancer, defined as biopsy Gleason score ≥7. First, we evaluated whether the addition of PHI improves the performance of currently available risk calculators (the Prostate Cancer Prevention Trial [ PCPT ] and European Randomised Study of Screening for Prostate Cancer [ ERSPC ] risk calculators). We also designed and internally validated a new PHI ‐based multivariable predictive model, and created a nomogram. Results Of 728 men undergoing biopsy, 118 (16.2%) had aggressive prostate cancer. The PHI predicted the risk of aggressive prostate cancer across the spectrum of values. Adding PHI significantly improved the predictive accuracy of the PCPT and ERSPC risk calculators for aggressive disease. A new model was created using age, previous biopsy, prostate volume, PSA and PHI , with an area under the curve of 0.746. The bootstrap‐corrected model showed good calibration with observed risk for aggressive prostate cancer and had net benefit on decision‐curve analysis. Conclusion Using PHI as part of multivariable risk assessment leads to a significant improvement in the detection of aggressive prostate cancer, potentially reducing harms from unnecessary prostate biopsy and overdiagnosis.
Expertise Matters
Manno, Edward M., Freeman, William D. , Livesay, Sarah , Geocadin, Romergryko G. , Torbey, Michel , Hemphill, Claude, Nyquist, Paul , Freeman, William D

Critical Care Medicine | October 15, 2016 | Volume: 44 | Issue: 11 | Pages: e1147-e1148

10.1097/ccm.0000000000001993 | PMID 27755089 Get It

Disclosing Huntington's Genetic Testing Results in the Context of Intellectual Disability and Guardianship: Using the Family Illness Narrative to Guide the Flow of Information
Warren, Mark, Schak, Kathryn M.

Journal of Genetic Counseling | October 15, 2016 | Volume: 26 | Issue: 2 | Pages: 272-275

10.1007/s10897-016-0007-1 | PMID 27744538 Get It

AbstractA diagnosis of Huntington's disease has broad social, vocational, reproductive and psychological implications. The ability to accurately diagnose the illness via genetic testing is not new. However, given a persistent lack of robustly effective interventions, it remains an area of ethical concern. The difficulty is compounded in cases of intellectual disability. This paper presents a case of genetic testing for Huntington's disease conducted on a patient with intellectual disability with guardian consent, but without the patient's direct knowledge and how the family illness narrative and psychiatric care were employed in the eventual disclosure of the patient's diagnosis and subsequent management.
Clinical Practice Guidelines for Sustained Neuromuscular Blockade in the Adult Critically Ill Patient
Murray, Michael J. , DeBlock, Heidi F., Erstad, Brian L. , Gray, Anthony, Jacobi, Judith , Jordan, Ché J., McGee, William T. , McManus, Claire, Meade, Maureen O. , Nix, Sean , Sands, M. Karen, Pino, Richard M. , Tescher, Ann, Arbour, Richard, Murray, Catherine Friederich, Mehta, Sangeeta , Patterson, Andrew J. , Rochwerg, Bram

Critical Care Medicine | October 15, 2016 | Volume: 44 | Issue: 11 | Pages: 2079-2103

10.1097/ccm.0000000000002027 | PMID 27755068 Get It

Objective: To update the 2002 version of “Clinical practice guidelines for sustained neuromuscular blockade in the adult critically ill patient.” Design: A Task Force comprising 17 members of the Society of Critical Medicine with particular expertise in the use of neuromuscular-blocking agents; a Grading of Recommendations Assessment, Development, and Evaluation expert; and a medical writer met via teleconference and three face-to-face meetings and communicated via e-mail to examine the evidence and develop these practice guidelines. Annually, all members completed conflict of interest statements; no conflicts were identified. This activity was funded by the Society for Critical Care Medicine, and no industry support was provided. Methods: Using the Grading of Recommendations Assessment, Development, and Evaluation system, the Grading of Recommendations Assessment, Development, and Evaluation expert on the Task Force created profiles for the evidence related to six of the 21 questions and assigned quality-of-evidence scores to these and the additional 15 questions for which insufficient evidence was available to create a profile. Task Force members reviewed this material and all available evidence and provided recommendations, suggestions, or good practice statements for these 21 questions. Results: The Task Force developed a single strong recommendation: we recommend scheduled eye care that includes lubricating drops or gel and eyelid closure for patients receiving continuous infusions of neuromuscular-blocking agents. The Task Force developed 10 weak recommendations. 1) We suggest that a neuromuscular-blocking agent be administered by continuous intravenous infusion early in the course of acute respiratory distress syndrome for patients with a Pa o 2 /F io 2 less than 150. 2) We suggest against the routine administration of an neuromuscular-blocking agents to mechanically ventilated patients with status asthmaticus. 3) We suggest a trial of a neuromuscular-blocking agents in life-threatening situations associated with profound hypoxemia, respiratory acidosis, or hemodynamic compromise. 4) We suggest that neuromuscular-blocking agents may be used to manage overt shivering in therapeutic hypothermia. 5) We suggest that peripheral nerve stimulation with train-of-four monitoring may be a useful tool for monitoring the depth of neuromuscular blockade but only if it is incorporated into a more inclusive assessment of the patient that includes clinical assessment. 6) We suggest against the use of peripheral nerve stimulation with train of four alone for monitoring the depth of neuromuscular blockade in patients receiving continuous infusion of neuromuscular-blocking agents. 7) We suggest that patients receiving a continuous infusion of neuromuscular-blocking agent receive a structured physiotherapy regimen. 8) We suggest that clinicians target a blood glucose level of less than 180 mg/dL in patients receiving neuromuscular-blocking agents. 9) We suggest that clinicians not use actual body weight and instead use a consistent weight (ideal body weight or adjusted body weight) when calculating neuromuscular-blocking agents doses for obese patients. 10) We suggest that neuromuscular-blocking agents be discontinued at the end of life or when life support is withdrawn. In situations in which evidence was lacking or insufficient and the study results were equivocal or optimal clinical practice varies, the Task Force made no recommendations for nine of the topics. 1) We make no recommendation as to whether neuromuscular blockade is beneficial or harmful when used in patients with acute brain injury and raised intracranial pressure. 2) We make no recommendation on the routine use of neuromuscular-blocking agents for patients undergoing therapeutic hypothermia following cardiac arrest. 3) We make no recommendation on the use of peripheral nerve stimulation to monitor degree of block in patients undergoing therapeutic hypothermia. 4) We make no recommendation on the use of neuromuscular blockade to improve the accuracy of intravascular-volume assessment in mechanically ventilated patients. 5) We make no recommendation concerning the use of electroencephalogram-derived parameters as a measure of sedation during continuous administration of neuromuscular-blocking agents. 6) We make no recommendation regarding nutritional requirements specific to patients receiving infusions of neuromuscular-blocking agents. 7) We make no recommendation concerning the use of one measure of consistent weight over another when calculating neuromuscular-blocking agent doses in obese patients. 8) We make no recommendation on the use of neuromuscular-blocking agents in pregnant patients. 9) We make no recommendation on which muscle group should be monitored in patients with myasthenia gravis receiving neuromuscular-blocking agents. Finally, in situations in which evidence was lacking or insufficient but expert consensus was unanimous, the Task Force developed six good practice statements. 1) If peripheral nerve stimulation is used, optimal clinical practice suggests that it should be done in conjunction with assessment of other clinical findings (e.g., triggering of the ventilator and degree of shivering) to assess the degree of neuromuscular blockade in patients undergoing therapeutic hypothermia. 2) Optimal clinical practice suggests that a protocol should include guidance on neuromuscular-blocking agent administration in patients undergoing therapeutic hypothermia. 3) Optimal clinical practice suggests that analgesic and sedative drugs should be used prior to and during neuromuscular blockade, with the goal of achieving deep sedation. 4) Optimal clinical practice suggests that clinicians at the bedside implement measure to attenuate the risk of unintended extubation in patients receiving neuromuscular-blocking agents. 5) Optimal clinical practice suggests that a reduced dose of an neuromuscular-blocking agent be used for patients with myasthenia gravis and that the dose should be based on peripheral nerve stimulation with train-of-four monitoring. 6) Optimal clinical practice suggests that neuromuscular-blocking agents be discontinued prior to the clinical determination of brain death.
Emerging concepts in smooth muscle contributions to airway structure and function: implications for health and disease
Prakash, Y. S. , Prakash, Y S

American Journal of Physiology-Lung Cellular and Molecular Physiology | October 15, 2016 | Volume: 311 | Issue: 6 | Pages: L1113-L1140

10.1152/ajplung.00370.2016 | PMID 27742732 Get It

Airway structure and function are key aspects of normal lung development, growth, and aging, as well as of lung responses to the environment and the pathophysiology of important diseases such as asthma, chronic obstructive pulmonary disease, and fibrosis. In this regard, the contributions of airway smooth muscle (ASM) are both functional, in the context of airway contractility and relaxation, as well as synthetic, involving production and modulation of extracellular components, modulation of the local immune environment, cellular contribution to airway structure, and, finally, interactions with other airway cell types such as epithelium, fibroblasts, and nerves. These ASM contributions are now found to be critical in airway hyperresponsiveness and remodeling that occur in lung diseases. This review emphasizes established and recent discoveries that underline the central role of ASM and sets the stage for future research toward understanding how ASM plays a central role by being both upstream and downstream in the many interactive processes that determine airway structure and function in health and disease.